Published in Eur J Nucl Med Mol Imaging on June 27, 2015
Yttrium-90 hepatic radioembolization: clinical review and current techniques in interventional radiology and personalized dosimetry. Br J Radiol (2016) 0.82
High impact of macroaggregated albumin-based tumour dose on response and overall survival in hepatocellular carcinoma patients treated with (90) Y-loaded glass microsphere radioembolization. Liver Int (2016) 0.80
Selective Internal Radiation Therapy With Yttrium-90 Glass Microspheres: Biases and Uncertainties in Absorbed Dose Calculations Between Clinical Dosimetry Models. Int J Radiat Oncol Biol Phys (2016) 0.76
Hepatobiliary scintigraphy may improve radioembolization treatment planning in HCC patients. EJNMMI Res (2017) 0.75
Transarterial radioembolization vs chemoembolization for hepatocarcinoma patients: A systematic review and meta-analysis. World J Hepatol (2016) 0.75
Personalized Dosimetry for Radionuclide Therapy Using Molecular Imaging Tools. Biomedicines (2016) 0.75
A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology (1983) 30.77
Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med (2013) 13.90
Predictive value of intratumoral 99mTc-macroaggregated albumin uptake in patients with colorectal liver metastases scheduled for radioembolization with 90Y-microspheres. J Nucl Med (2013) 4.69
Complication probability as assessed from dose-volume histograms. Radiat Res Suppl (1985) 3.85
99mTc-macroaggregated albumin poorly predicts the intrahepatic distribution of 90Y resin microspheres in hepatic radioembolization. J Nucl Med (2013) 2.37
Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology (2013) 2.30
Partial volume tolerance of the liver to radiation. Semin Radiat Oncol (2005) 1.85
Intrinsic radiosensitivity of human cell lines is correlated with radioresponsiveness of human tumors: analysis of 101 published survival curves. Int J Radiat Oncol Biol Phys (1985) 1.79
Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med (2005) 1.55
Analysis of clinical complication data for radiation hepatitis using a parallel architecture model. Int J Radiat Oncol Biol Phys (1995) 1.54
Radioembolisation with 90Y-microspheres: dosimetric and radiobiological investigation for multi-cycle treatment. Eur J Nucl Med Mol Imaging (2008) 1.51
Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic tumours. Eur J Nucl Med (1996) 1.44
Efficacy and toxicity related to treatment of hepatocellular carcinoma with 90Y-SIR spheres: radiobiologic considerations. J Nucl Med (2010) 1.42
MIRD pamphlet No. 23: quantitative SPECT for patient-specific 3-dimensional dosimetry in internal radionuclide therapy. J Nucl Med (2012) 1.40
Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results. J Nucl Med (2012) 1.39
Partial irradiation of the liver. Semin Radiat Oncol (2001) 1.35
Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres: a phase I and II study. Br J Cancer (1994) 1.33
Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med (1983) 1.28
Implications of nonuniform tumor doses for radioimmunotherapy. J Nucl Med (1999) 1.25
Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: biological lessons, current challenges, and clinical perspectives. Hepatology (2013) 1.23
Multimodality imaging can predict the metabolic response of unresectable colorectal liver metastases to radioembolization therapy with Yttrium-90 labeled resin microspheres. Phys Med Biol (2008) 1.22
Post-radioembolization yttrium-90 PET/CT - part 2: dose-response and tumor predictive dosimetry for resin microspheres. EJNMMI Res (2013) 1.14
Need, feasibility and convenience of dosimetric treatment planning in liver selective internal radiation therapy with (90)Y microspheres: the experience of the National Tumor Institute of Milan. Q J Nucl Med Mol Imaging (2011) 1.10
Radioembolization of liver tumors with yttrium-90 microspheres. Semin Nucl Med (2010) 1.06
EANM Dosimetry Committee guidance document: good practice of clinical dosimetry reporting. Eur J Nucl Med Mol Imaging (2010) 1.05
EANM procedure guidelines for therapy of benign thyroid disease. Eur J Nucl Med Mol Imaging (2010) 1.02
A dosimetric treatment planning strategy in radioembolization of hepatocarcinoma with 90Y glass microspheres. Q J Nucl Med Mol Imaging (2012) 1.01
Hemoglobin level significantly impacts the tumor cell survival fraction in humans after internal radiotherapy. EJNMMI Res (2012) 1.01
Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept. Eur J Nucl Med Mol Imaging (2013) 0.99
Quantitative radioiodine therapy in the treatment of differentiated thyroid cancer. Q J Nucl Med (1999) 0.92
Estimate of radiobiologic parameters from clinical data for biologically based treatment planning for liver irradiation. Int J Radiat Oncol Biol Phys (2008) 0.91
Dose-rate effects in targeted radiotherapy. Phys Med Biol (1996) 0.91
Radioembolization of hepatic lesions from a radiobiology and dosimetric perspective. Front Oncol (2014) 0.91
Conformal radiotherapy of the dominant liver metastasis: a viable strategy for treatment of unresectable chemotherapy refractory colorectal cancer liver metastases. Am J Clin Oncol (2006) 0.90
A Comparison of Techniques for (90)Y PET/CT Image-Based Dosimetry Following Radioembolization with Resin Microspheres. Front Oncol (2014) 0.90
The low hepatic toxicity per Gray of 90Y glass microspheres is linked to their transport in the arterial tree favoring a nonuniform trapping as observed in posttherapy PET imaging. J Nucl Med (2013) 0.84
A hepatic dose-toxicity model opening the way toward individualized radioembolization planning. J Nucl Med (2014) 0.84
Treatment plan comparison using equivalent uniform biologically effective dose (EUBED). Phys Med Biol (2000) 0.83
The dosimetric importance of the number of 90Y microspheres in liver transarterial radioembolization (TARE). Eur J Nucl Med Mol Imaging (2014) 0.78
Differences in 3D dose distributions due to calculation method of voxel S-values and the influence of image blurring in SPECT. Phys Med Biol (2015) 0.77
A comparison of dose-response characteristics of four NTCP models using outcomes of radiation-induced optic neuropathy and retinopathy. Radiat Oncol (2011) 0.75
Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst (1999) 4.04
Canine kidney transplantation with FK-506 alone or in combination with cyclosporine and steroids. Transplant Proc (1987) 3.55
Benzo-gamma-pyrone analogues of geiparvarin: synthesis and biological evaluation against B16 melanoma cells. Anticancer Drug Des (1993) 2.79
[Yield of laboratory tests in the detection of excessive drinkers in the work place]. Med Clin (Barc) (1993) 2.64
[Analysis of quality and contents of the report of hospital discharge]. Med Clin (Barc) (1993) 2.62
Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management. J Natl Cancer Inst (2001) 2.57
Hepatotrophic effects of FK506 in dogs. Transplantation (1991) 2.39
Percutaneous radio-frequency thermal ablation of nonresectable hepatocellular carcinoma after occlusion of tumor blood supply. Radiology (2000) 2.15
Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Ann Oncol (2006) 2.10
Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol (1995) 2.09
Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev (2010) 2.09
Community prevalence survey of children's blood lead levels and environmental lead contamination in inner Sydney. Med J Aust (1992) 1.95
Efficiency of liver transplantation in patients with primary biliary cirrhosis. N Engl J Med (1989) 1.94
Toward a better liver graft allocation that accounts for candidates with and without hepatocellular carcinoma. Am J Transplant (2014) 1.77
Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines. J Natl Cancer Inst (1995) 1.63
Lung function predicts lung cancer risk in smokers: a tool for targeting screening programmes. Eur Respir J (2009) 1.62
Search for supersymmetry using final states with one lepton, jets, and missing transverse momentum with the ATLAS detector in √s=7 TeV pp collisions. Phys Rev Lett (2011) 1.60
Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol (1987) 1.57
Protein HU binds specifically to kinked DNA. Mol Microbiol (1993) 1.56
Placement of long-term central venous catheters in outpatients: study of 134 patients over 24,596 catheter days. AJR Am J Roentgenol (1997) 1.55
Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer (1999) 1.54
Protein repletion and treatment in anorexia nervosa. Am J Clin Nutr (1994) 1.50
Total rectal resection and complete mesorectum excision followed by coloendoanal anastomosis as the optimal treatment for low rectal cancer: the experience of the National Cancer Institute of Milano. Ann Surg Oncol (2000) 1.45
Radiation dose to technicians per nuclear medicine procedure: comparison between technetium-99m, gallium-67, and iodine-131 radiotracers and fluorine-18 fluorodeoxyglucose. Eur J Nucl Med (1997) 1.42
Blood lead concentrations and iron status of preschool children from low income families. Med J Aust (1997) 1.42
Observation of a centrality-dependent dijet asymmetry in lead-lead collisions at sqrt[S(NN)] =2.76 TeV with the ATLAS detector at the LHC. Phys Rev Lett (2010) 1.41
Hepatitis B vaccine. Med J Aust (1992) 1.40
Iron deficiency in Australian-born children of Arabic background in central Sydney. Med J Aust (2001) 1.40
Measurement of dijet azimuthal decorrelations in pp collisions at sqrt(s)=7 TeV. Phys Rev Lett (2011) 1.39
Stereotactic excisional breast biopsy performed by interventional radiologists using the advanced breast biopsy instrumentation system. Br J Radiol (1998) 1.39
Rapid Flush Technique for Donor Hepatectomy: Safety and Efficacy of an Improved Method of Liver Recovery for Transplantation. Transplant Proc (1988) 1.37
FK 506 as a growth control factor. Transplant Proc (1990) 1.36
Determination of the strange-quark density of the proton from ATLAS measurements of the W→ℓν and Z→ℓℓ cross sections. Phys Rev Lett (2012) 1.34
Spindle cell lipoma of the hypopharynx. Dysphagia (2001) 1.34
A model for the evaluation of computerised codes. The Gabrieli Medical Nomenclature as an example. Aust Fam Physician (1997) 1.34
Contribution of reduced insulin sensitivity and secretion to the pathogenesis of hepatogenous diabetes: effect of liver transplantation. Hepatology (2000) 1.32
Search for new particles in two-jet final states in 7 TeV proton-proton collisions with the ATLAS detector at the LHC. Phys Rev Lett (2010) 1.32
Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series. Ann Oncol (2009) 1.31
Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study. Oral Oncol (2008) 1.31
Response to imatinib plus sirolimus in advanced chordoma. Ann Oncol (2009) 1.30
Observation of associated near-side and away-side long-range correlations in sqrt[s(NN)]=5.02 TeV proton-lead collisions with the ATLAS detector. Phys Rev Lett (2013) 1.27
Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect. Ann Oncol (2011) 1.24
The quality of communication between hospitals and general practitioners: an assessment. J Qual Clin Pract (1998) 1.22
Search for dark matter candidates and large extra dimensions in events with a photon and missing transverse momentum in pp collision data at sqrt[s]=7 TeV with the ATLAS detector. Phys Rev Lett (2013) 1.19
Failure of the phagocytic oxidative response to protect human monocyte-derived macrophages from infection by Leishmania donovani. J Immunol (1982) 1.19
Prolongation of pig-to-dog renal xenograft survival by modification of the inflammatory mediator response. Ann Surg (1987) 1.19
Synthesis of flavone-2'-carboxylic acid analogues as potential antitumor agents. Anticancer Drug Des (1998) 1.19
Childbearing after liver transplantation. Transplantation (1990) 1.19
Comparison of three different methods for radiolabelling human activated T lymphocytes. Eur J Nucl Med (1997) 1.18
Pattern and management of recurrent hepatocellular carcinoma after liver transplantation. J Hepatobiliary Pancreat Surg (1998) 1.17
Transplantation of the liver for metastatic endocrine tumors of the intestine and pancreas. Surg Gynecol Obstet (1989) 1.17
Patient safety events reported in general practice: a taxonomy. Qual Saf Health Care (2008) 1.17
Isolation of the epithiospecifier protein from oil-rape (Brassica napus ssp. oleifera) seed and its characterization. FEBS Lett (2000) 1.17
Phase II study on lapatinib in advanced EGFR-positive chordoma. Ann Oncol (2013) 1.16
Continuity of care in diabetes: to whom does it matter? Diabetes Res Clin Pract (2001) 1.16
Renal artery reconstruction for harvesting injuries in kidney transplantation with particular reference to the use of vascular allografts. Transpl Int (1988) 1.14
Search for a supersymmetric partner to the top quark in final states with jets and missing transverse momentum at sqrt[s] = 7 TeV with the ATLAS detector. Phys Rev Lett (2012) 1.13
Interstitial lung diseases in a lung cancer screening trial. Eur Respir J (2011) 1.13
Sunitinib malate in solitary fibrous tumor (SFT). Ann Oncol (2012) 1.12
Chemoembolization of hepatocellular carcinoma in patients who undergo liver transplantation. Radiology (1994) 1.12
Can GP input into discharge planning result in better outcomes for the frail aged: results from a randomized controlled trial. Fam Pract (1999) 1.12
Molecular structure and cytotoxicity of 3D-transition metal complexes capable to form a stable metal-nitrogen bond. Nucleosides Nucleotides Nucleic Acids (2000) 1.11
Association between [18F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation. Eur J Nucl Med (1998) 1.11
Recovery after childbirth: a preliminary prospective study. Med J Aust (1990) 1.11
Reappraisal of surgical treatment of small hepatocellular carcinomas in cirrhosis: clinicopathological study of resection or transplantation. Dig Dis Sci (1989) 1.10
Interaction of Leishmania donovani promastigotes with human monocyte-derived macrophages: parasite entry, intracellular survival, and multiplication. Infect Immun (1981) 1.10
Need, feasibility and convenience of dosimetric treatment planning in liver selective internal radiation therapy with (90)Y microspheres: the experience of the National Tumor Institute of Milan. Q J Nucl Med Mol Imaging (2011) 1.10
The primary structure of UK114 tumor antigen. FEBS Lett (1996) 1.10
Perinatal and environmental factors in late neurogenic sequelae. I. Infants having birth weights under 1,500 grams. Am J Dis Child (1966) 1.09
Search for tb resonances in proton-proton collisions at √s=7 TeV with the ATLAS detector. Phys Rev Lett (2012) 1.07
A novel mutation in the ATP1A2 gene causes alternating hemiplegia of childhood. J Med Genet (2004) 1.07
Structure of L-aspartate oxidase: implications for the succinate dehydrogenase/fumarate reductase oxidoreductase family. Structure (1999) 1.07
Circulating immune complexes and rheumatoid factors in visceral leishmaniasis. J Infect Dis (1983) 1.05
Search for a light Higgs boson decaying to long-lived weakly interacting particles in proton-proton collisions at sqrt[s] = 7 TeV with the ATLAS detector. Phys Rev Lett (2012) 1.05